{"id":"comparator-dorzolamide-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular burning or stinging"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Tearing"},{"rate":null,"effect":"Bitter taste"},{"rate":null,"effect":"Ocular allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carbonic anhydrase is an enzyme that catalyzes the production of aqueous humor in the ciliary body of the eye. By inhibiting this enzyme, dorzolamide decreases aqueous humor secretion, which lowers intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension, conditions where elevated intraocular pressure can damage the optic nerve.","oneSentence":"Dorzolamide hydrochloride inhibits carbonic anhydrase II in the eye, reducing aqueous humor production and lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:55.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03034772","phase":"PHASE2, PHASE3","title":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-02-08","conditions":"Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":52},{"nctId":"NCT00449956","phase":"PHASE3","title":"MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-12","conditions":"Glaucoma","enrollment":474},{"nctId":"NCT00546286","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":170},{"nctId":"NCT00108017","phase":"PHASE3","title":"Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: dorzolamide hydrochloride","genericName":"Comparator: dorzolamide hydrochloride","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dorzolamide hydrochloride inhibits carbonic anhydrase II in the eye, reducing aqueous humor production and lowering intraocular pressure. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}